Drug delivery device

• US 6,413,540 B1
• Filed: 09/12/2000
• Issued: 07/02/2002
• Est. Priority Date: 10/21/1999
• Status: Expired due to Term

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Universal Ltd.
• Inventors: Yaacobi, Yoseph
• Primary Examiner(s): Spear, James M.
• Application Number:
  US09/660,000
• Time in Patent Office: 658 Days
• Field of Search: 424/423, 424/427
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.

Claims

1. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α

,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α

,21-diol-3,20-dione-21-acetate.

2. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises eliprodil.

3. A method of delivering a pharmaceutically active agent to an eye, said eye having a sclera, comprising the steps of:

providing a drug delivery device comprising;

a body having a scleral surface and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent; and

disposing said device within said eye so that said pharmaceutically active agent is in communication with said sclera through said opening.

4. The method of claim 3 wherein said body comprises a biocompatible, non-bioerodable material.

5. The method of claim 3 wherein said inner core is a tablet.

6. The method of claim 3 wherein said inner core comprises a hydrogel, and said pharmaceutically active agent is disposed within said hydrogel.

7. The method of claim 3 wherein said body is impermeable to said pharmaceutically active agent.

8. The method of claim 3 wherein said disposing step comprises disposing said scleral surface in contact with said sclera.

9. The method of claim 8 wherein said scleral surface has a geometry that mates with said sclera.

10. The method of claim 3 wherein said disposing step comprises disposing said inner core in contact with said sclera.

11. The method of claim 3 wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α

,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α

,21-diol-3,20-dione-21-acetate.

12. The method of claim 3 wherein said pharmaceutically active agent comprises eliprodil.

13. The method of claim 8 wherein said eye is a human eye having a macula, and said disposing step comprises disposing said device generally above said macula.

14. The method of claim 3 wherein said eye is a human eye having a choroid and a retina, and further comprising the step of delivering a pharmaceutically effective amount of said pharmaceutically active agent through said sclera and said choroid and to said retina over a period of time.

15. A method of delivering a pharmaceutically active agent to the eye, said eye having a sclera, a Tenon'"'"'s capsule, and a macula, comprising the steps of:

providing a drug delivery device comprising a body having a pharmaceutically active agent disposed therein; and

disposing said device on an outer surface of said sclera, below said Tenon'"'"'s capsule, and proximate said macula.

16. The method of claim 15 wherein said disposing step comprises disposing said device generally above said macula.